Covered recipient · General Payments record
LALASA R VALASAREDDI
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$995.10
- Reported across 37 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $386.73 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $167.16 | 7 |
| Lilly USA, LLC | $75.29 | 3 |
| Acerta Pharma LLC | $56.57 | 3 |
| GlaxoSmithKline, LLC. | $45.11 | 2 |
| Novo Nordisk AS | $21.74 | 1 |
| Merck Sharp & Dohme Corporation | $20.86 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $31.38 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117404263 | CMS |
| Amgen Inc. | $31.43 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117404265 | CMS |
| Amgen Inc. | $18.42 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117404267 | CMS |
| Amgen Inc. | $20.18 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117404269 | CMS |
| Amgen Inc. | $22.71 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117404271 | CMS |
| Amgen Inc. | $20.90 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117404273 | CMS |
| Amgen Inc. | $22.14 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117404275 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.44 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105648586 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.91 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104668751 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.22 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104494628 | CMS |
| GlaxoSmithKline, LLC. | $20.11 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116298108 | CMS |
| GlaxoSmithKline, LLC. | $25.00 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116548945 | CMS |
| Lilly USA, LLC | $25.05 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135140114 | CMS |
| Lilly USA, LLC | $22.90 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135140112 | CMS |
| Lilly USA, LLC | $27.34 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135082510 | CMS |
| Merck Sharp & Dohme LLC | $20.86 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141672593 | CMS |
| Novo Nordisk Inc | $21.74 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097305783 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.